Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Grillo

Showing results (11-20 of 84) with videos related to

Pageof 9
Sort By:
ACS Medicinal Chemistry Letters|December 20, 2023
Development of Allosteric NIK Ligands from Fragment-Based NMR ScreeningJared J Anderson, Michael J Grillo, Daniel A Harki
Seminars in Oncology|November 24, 1999
Rituximab in indolent lymphoma: the single-agent pivotal trialP McLaughlin, F B Hagemeister, A J Grillo-López
Current Pharmaceutical Biotechnology|July 27, 2001
Antibody-targeted immunotherapy for treatment of non-Hodgkin's lymphomaC A White, J R Berlfein, A J Grillo-López
Seminars in Oncology|February 1, 2017
Rituximab: Ongoing and future clinical developmentAntonio J Grillo-López, Eric Hedrick, Michelle Rashford, et al.
Investigational New Drugs|January 1, 1986
CI-921: an analog of amsacrine with experimental activity against solid tumorsW R Grove, L W DeLap, A J Grillo-López
Annual Review of Medicine|February 13, 2001
Antibody-targeted immunotherapy for treatment of malignancyC A White, R L Weaver, A J Grillo-López
Seminars in Oncology|February 14, 2002
Rituximab: ongoing and future clinical developmentAntonio J Grillo-López, Eric Hedrick, Michelle Rashford, et al.
Investigational New Drugs|January 1, 1983
Diaziquone (AZQ)J F Bender, A J Grillo-Lopez, J G Posada
Investigational New Drugs|January 1, 1985
A phase I trial of ametantrone acetate (NSC-287513)R A Gams, F Ostroy, J F Bender, et al.
Oncology (Williston Park, N.Y.)|January 6, 1999
Clinical status and optimal use of rituximab for B-cell lymphomasP McLaughlin, C A White, A J Grillo-López, et al.
Pageof 9

Showing results (11-20 of 84) with videos related to

Sort By:
Pageof 9
ACS Medicinal Chemistry Letters|December 20, 2023
Development of Allosteric NIK Ligands from Fragment-Based NMR ScreeningJared J Anderson, Michael J Grillo, Daniel A Harki
Seminars in Oncology|November 24, 1999
Rituximab in indolent lymphoma: the single-agent pivotal trialP McLaughlin, F B Hagemeister, A J Grillo-López
Current Pharmaceutical Biotechnology|July 27, 2001
Antibody-targeted immunotherapy for treatment of non-Hodgkin's lymphomaC A White, J R Berlfein, A J Grillo-López
Seminars in Oncology|February 1, 2017
Rituximab: Ongoing and future clinical developmentAntonio J Grillo-López, Eric Hedrick, Michelle Rashford, et al.
Investigational New Drugs|January 1, 1986
CI-921: an analog of amsacrine with experimental activity against solid tumorsW R Grove, L W DeLap, A J Grillo-López
Annual Review of Medicine|February 13, 2001
Antibody-targeted immunotherapy for treatment of malignancyC A White, R L Weaver, A J Grillo-López
Seminars in Oncology|February 14, 2002
Rituximab: ongoing and future clinical developmentAntonio J Grillo-López, Eric Hedrick, Michelle Rashford, et al.
Investigational New Drugs|January 1, 1983
Diaziquone (AZQ)J F Bender, A J Grillo-Lopez, J G Posada
Investigational New Drugs|January 1, 1985
A phase I trial of ametantrone acetate (NSC-287513)R A Gams, F Ostroy, J F Bender, et al.
Oncology (Williston Park, N.Y.)|January 6, 1999
Clinical status and optimal use of rituximab for B-cell lymphomasP McLaughlin, C A White, A J Grillo-López, et al.
Pageof 9